173950-08-8

Upstream product

• 123-34-2 (R)-3-allyloxypropane-1,2-diol 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 56083-15-9 (S)-4-((allyloxy)methyl)-2,2-dimethyl-1,3-dioxolane 

Downstream Products

• 106401-57-4 1-O-allyl-2-O-benzyl-sn-glycerol 
• 173950-09-9 Trifluoro-methanesulfonic acid (S)-3-allyloxy-2-benzyloxy-propyl ester 

Relevant academic research and scientific papers

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Macrocyclic MCL-1 inhibitors and methods of use

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of formula (I), wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Synthesis of novel mimetics of the sialyl Lewis X determinant

Mimetics of the sialyl Lewis-X determinant in which at least one sugar domain is simulated by a di-, tri- or tetraalcohol unit have been synthesized. The inhibitory potency of these compounds for E- and P-selectin mediated cell adhesion has been evaluated in cell culture assays. The receptor binding affinity of the best of these mimetics was slightly higher than that of the natural oligosaccharide ligand sialyl Lewis X.